Business Context and Reporting Period
Company: Halozyme Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 16, 2004
Reporting Period: The filing references financial results for the three and six months ended June 30, 2004, though the specific numerical data is contained in an attached press release (Exhibit 99.2) and not explicitly detailed in the text of this 8-K.
Key Financial Metrics
The text of this filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being contained in the press release attached as Exhibit 99.2.
Material Changes and Events
- Strategic Agreement: On August 16, 2004, the company signed an exclusive sales and marketing agreement with Baxter Healthcare Corporation for its product Enhance SC(TM).
- Financial Reporting: The company issued a press release reporting financial results for the periods ended June 30, 2004.
Guidance, Outlook, and Risks
The filing text does not contain specific management commentary, forward-looking guidance, risk factors, or contingencies beyond the announcement of the new agreement and the release of past financial results. The press release containing financial results is furnished under Item 12 and is explicitly stated not to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.2 (Press Release dated August 16, 2004) for specific revenue, net loss, and cash position figures for the three and six months ended June 30, 2004.
- Examine Exhibit 99.1 for the specific terms, duration, and financial implications of the exclusive sales and marketing agreement with Baxter Healthcare Corporation.
- Verify the commercial status and regulatory approval of Enhance SC(TM) to assess the immediate impact of the Baxter agreement.